Life Sciences CLE Webinar Series
Haug Partners is excited to announce that the first installment of our new Life Sciences CLE Program took place on February 20, 2025 and was a great success. We’d like to thank everyone for attending and look forward to announcing our next webinar.
During this quarterly CLE program, thought-leaders will delve into key issues shaping intellectual property in biotechnology, pharmaceuticals, and medical devices in order to provide critical insights into patent strategies, regulatory developments, and litigation trends impacting the life sciences sector. Designed for legal professionals and industry leaders, this program ensures you’re prepared to navigate the rapidly evolving IP landscape. New York CLE credits will be available.
Is there a topic you’re eager to explore? Let us know! Submit your ideas for a future CLE session and help us deliver content most useful to your business. Use the form below to stay informed about the Life Sciences CLE program, be notified for our newest webinar, and to submit suggestions.
Don’t Miss Out – Get Notified About Upcoming Life Sciences CLEs
Past CLEs
Review of Enablement Standard Post-Amgen and Implications for Patent Claim Strategies and Litigation
Presented by Wan Chieh (Jenny) Lee and Kaitlin Farrell
February 20, 2025 | 1:00 PM
During this webinar session, the panelists will briefly revisit the Supreme Court’s 2023 decision in Amgen v. Sanofi and dive into how the enablement standard has been applied post-Amgen. The panel will discuss the impact of Amgen and potential strategies for navigating the enablement requirement from drafting to litigation.
What You’ll Learn:
- The current state of the enablement standard post-Amgen
- Impact of the Amgen decision beyond antibody technology
- Potential drafting and litigation strategies for navigating the enablement requirement
Program Faculty
Kaitlin Farrell, Partner
Kaitlin Farrell is a Partner in our New York office. Kaitlin’s practice focuses on complex patent and intellectual property litigation, with a particular emphasis on life sciences and pharmaceutical patent litigation.
Wan Chieh (Jenny) Lee, Partner
Wan Chieh (Jenny) Lee combines extensive experience across all aspects of patent law with a strong ability to analyze complex technical information to provide clients with business-oriented patent strategies and insights.
Andrew Roper, Partner
Andrew Roper is a partner in Haug Partners’ New York offices. The majority of his practice focuses on patent litigation. Additionally, he performs due diligences, and evaluations of IP assets.
Andrew Wasson, Partner
Andrew Wasson is a partner and Chair of Haug Partners’ FDA practice in the New York office. Andrew has a broad range of experience in both the brand and generic side of pharmaceuticals, especially with respect to issues involving intellectual property law and regulatory law.
